Introduction Kidney and simultaneous pancreas kidney (SPK) transplant recipients are younger and fitter than most other dialysis patients, but are also more vulnerable in areas of social, emotional and physical interaction. Few studies have tracked their post‐transplant health‐related quality of life (HRQoL). Aim To assess HRQoL following kidney and SPK transplantation, with comparison to dialysis patients, people with multiple co‐morbidities and general population data. Methods Patients completed the Kidney Disease Quality of Life Short Form (KDQOL‐SF™) 1.3 to assess their pre‐transplant HRQoL within 4 weeks of transplantation and 12 months later. Demographic and laboratory data were collected on participating patients and on non‐participating patients at both time‐points. Results Of 118 patients who completed the baseline KDQOL‐SF™, 75 (57 kidney and 18 SPK) completed the 1 year survey. Compared to baseline, 12 months HRQoL scores improved in all domains except for work status, exceeded those of patients on dialysis and, except for emotional wellbeing and mental health, exceeded the scores of people with multiple co‐morbidities. For female transplant recipients, 12 months HRQoL scores were not statistically different from similarly aged women in the general population. Male transplant recipients had similar scores for bodily pain and energy/fatigue, but lower scores in other domains. Compared to kidney‐only transplant recipients, SPK recipients achieved higher scores in work and sleep domains. Conclusion Improvements in most HRQoL domains occur within 1 year of kidney or SPK transplantation, and women achieve similar HRQoL to women in the general population. These data are encouraging for patients contemplating transplant listing.

Acute kidney injury is rarely the presenting feature of sarcoidosis. We present a case series of patients whose diagnosis of sarcoidosis was only brought to light by the development of renal impairment. Concurrent hypercalcaemia was noted, prompting further investigation. The patients discussed experienced a significant and rapid improvement in both renal function and hypercalcaemia in response to therapy with prednisolone. This is out of keeping with previous reports of sarcoidosis-induced renal impairment. Our case series highlights the importance of testing for hypercalcaemia in the context of acute kidney injury. Sarcoidosis is primarily a disease of the lungs and reticuloendothelial system; however, the prevalence of renal involvement with sarcoidosis may be under-recognized. The renal manifestations of sarcoidosis are discussed in the context of the current literature. Furthermore, from our experience, we postulate that in the context of sarcoidosis-induced renal injury, concurrent hypercalcaemia may present prior to the development of chronic renal injury and therefore these patients may be more likely to recover renal function.

Background Pregnant women at high risk for developing a hypertensive disorder of pregnancy require frequent antenatal assessments, especially of their blood pressure. This expends significant resources for both the patient and healthcare system. An alternative to in-clinic assessments is a remote blood pressure monitoring strategy, in which patients self-record their blood pressure at home using a validated blood pressure machine. This has the potential to be cost-effective, increase patient satisfaction, and reduce outpatient visits, and has had widespread uptake recently given the increased need for remote care during the ongoing COVID-19 pandemic. However robust evidence supporting this approach over a traditional face-to-face approach is lacking, and the impact on maternal and foetal outcomes has not yet been reported. Thus, there is an urgent need to assess the efficacy of remote monitoring in pregnant women at high risk of developing a hypertensive disorder of pregnancy. Methods The REMOTE CONTROL trial is a pragmatic, unblinded, randomised controlled trial, which aims to compare remote blood pressure monitoring in high-risk pregnant women with conventional face-to-face clinic monitoring, in a 1:1 allocation ratio. The study will recruit patients across 3 metropolitan Australian teaching hospitals and will evaluate the safety, cost-effectiveness, impact on healthcare utilisation and end-user satisfaction of remote blood pressure monitoring. Discussion Remote blood pressure monitoring is garnering interest worldwide and has been increasingly implemented following the COVID-19 pandemic. However, robust data regarding its safety for maternofoetal outcomes is lacking. The REMOTE CONTROL trial is amongst the first randomised controlled trials currently underway, powered to evaluate maternal and foetal outcomes. If proven to be as safe as conventional clinic monitoring, major potential benefits include reducing clinic visits, waiting times, travel costs, and improving delivery of care to vulnerable populations in rural and remote communities. Trial registration The trial has been prospectively registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12620001049965p, on October 11th, 2020).